# 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study

> **NCT05496959** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 93 (actual)

## Conditions studied

- Oligometastatic Prostate Carcinoma
- Prostate Adenocarcinoma
- Recurrent Prostate Adenocarcinoma
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Lutetium Lu-177 PNT2002
- **OTHER:** Quality-of-Life Assessment
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT05496959
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-02
- **Primary completion:** 2032-09-01
- **Final completion:** 2033-09-01
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2025-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05496959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05496959, "177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05496959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*